Objective Evaluate the clinical utility of combinatorial pharmacogenomic testing for informing
medication selection among older adults who have experienced antidepressant medication
failure for major depressive disorder (MDD). Design Post hoc analysis of data from a
blinded, randomized controlled trial comparing two active treatment arms. Setting Psychiatry
specialty and primary care clinics across 60 US community and academic sites. Participants
Adults age 65 years or older at baseline (n= 206), diagnosed with MDD and inadequate …

Objective: Evaluate the clinical utility of combinatorial pharmacogenomic testing for
informing medication selection among older adults who have experienced antidepressant
medication failure for major depressive disorder (MDD). Design: Post hoc analysis of data
from a blinded, randomized controlled trial comparing two active treatment arms. Setting:
Psychiatry specialty and primary care clinics across 60 US community and academic sites.
Participants: Adults age 65 years or older at baseline (n= 206), diagnosed with MDD and …